General Neurology
Hypoparathyroidism
May. 14, 2024
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Transverse myelitis is a neurological disorder caused by inflammation of the spinal cord, the part of the central nervous system that sends impulses from the brain to nerves in the body. The spinal cord also carries sensory information back to the brain.
Myelitis refers to inflammation of the spinal cord. It can damage the insulating material, called myelin, that covers nerve cell fibers. Transverse refers to the pattern of changes in sensation—there is often a band-like sensation across the trunk of the body, with sensory changes below that area.
The segment of the spinal cord at which the damage occurs determines which parts of the body are affected. Damage at one segment will affect function at that level and below. In people with transverse myelitis, myelin damage most often occurs in nerves in the upper back.
Although some people recover from transverse myelitis with minor or no residual problems, the healing process may take months to years. Most people with transverse myelitis have at least partial recovery, with most recovery taking place within the first three months after the attack. Other people may have permanent impairments that affect their ability to perform ordinary tasks of daily living. Some people will have only one episode of transverse myelitis, but others may have a recurrence, especially if an underlying illness caused the disorder.
Transverse myelitis may be either acute (developing over hours to several days) or subacute (usually developing over one to four weeks).
Four classic features of transverse myelitis are:
Many people also report having muscle spasms, a general feeling of discomfort, headache, fever, and loss of appetite, while some people experience respiratory problems. Other symptoms may include sexual dysfunction, depression or anxiety caused by lifestyle changes, stress, and chronic pain.
Who is more likely to get transverse myelitis?
Transverse myelitis can affect people of any age, gender, or race. It does not appear to be genetic or to run in families. The disorder occurs most frequently in people who are either between ages 10 and 19 years old or between 30 and 39 years old.
The following conditions appear to cause transverse myelitis:
The exact cause of transverse myelitis and extensive damage to the bundles of nerve fibers of the spinal cord is unknown in many cases. When doctors cannot identify a cause for the disorder, they refer to it as idiopathic, which means the cause is unknown.
In some people, transverse myelitis is the first symptom of an autoimmune or immune-mediated disease such as multiple sclerosis or neuromyelitis optica.
“Partial” myelitis, which affects only a portion of the spinal cord cross-section, is more common with multiple sclerosis.
“Complete” myelitis, where there is severe paralysis and numbness on both sides of the spinal cord, is more likely to be a symptom of neuromyelitis optica. Myelitis attacks with neuromyelitis optica spectrum disorder (NMOSD) tend to be more severe than attacks caused by multiple sclerosis, and people are less likely to have a complete recovery.
How is transverse myelitis diagnosed and treated?
Diagnosing transverse myelitis. Physicians diagnose transverse myelitis by taking a medical history and performing a thorough neurological examination. These tests can indicate a diagnosis of transverse myelitis and rule out or evaluate underlying causes:
Treating transverse myelitis. There is no cure for transverse myelitis, but there are treatments to prevent or minimize permanent neurological problems.
Treatments are designed to address infections that may cause the disorder, reduce spinal cord inflammation, and manage and reduce symptoms.
These are some of the most common initial treatments for transverse myelitis:
Following initial therapy, it is critical to keep the person's body functioning during the recovery period. In rare cases when breathing is significantly affected, the person may be placed on a respirator.
Multiple sclerosis and neuromyelitis optica typically require long-term treatment to modify the immune system response. Treatment of MS with immumodulatory or immunosuppressant medications such as alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, interferon-beta, natalizumab, or teriflunomide may be needed.
Immunosuppressant treatments are used for neuromyelitis optica spectrum disorder and recurrent episodes of transverse myelitis that are not caused by multiple sclerosis. They are aimed at preventing future myelitis attacks (or immune attacks on other parts of the body) and they may include steroid-sparing drugs such as mycophenolate mofetil, azathioprine, and rituximab.
Rehabilitation and long-term therapy
Many forms of long-term rehabilitation are available for people who have disabilities resulting from transverse myelitis. Strength and functioning may improve with rehabilitation services, even years after the initial episode.
Although rehabilitation cannot reverse the physical damage resulting from transverse myelitis, it can help people, even those with severe paralysis, become as functionally independent as possible and attain the best possible quality of life.
People with lasting or permanent neurological defects from transverse myelitis typically see a range of rehabilitation specialists, which may include physiatrists, physical therapists, occupational therapists, vocational therapists, and mental health care professionals.
What are the latest updates on transverse myelitis?
NINDS funding supports researchers who work to understand how the immune system destroys or attacks the nerve-insulating substance called myelin in autoimmune diseases or disorders. Other research focuses on strategies to repair demyelinated spinal cords, including approaches that use cell transplantation. This research may lead to a greater understanding of the mechanisms that damage myelin. It may ultimately provide a means to prevent and improve treatments for transverse myelitis.
More information on transverse myelitis and spinal cord injury research is available through the NIH RePORTER, a searchable database of current and previously funded research, as well as research results and publications.
How can I or my loved one help improve care for people with transverse myelitis?
Consider participating in a clinical trial so clinicians and scientists can learn more about transverse myelitis. Clinical research uses human volunteers to help researchers learn more about a disorder and perhaps find better ways to safely detect, treat, or prevent disease.
All types of volunteers are needed—those who are healthy or may have an illness or disease—of all different ages, sexes, races, and ethnicities to ensure that study results apply to as many people as possible, and that treatments will be safe and effective for everyone who will use them.
For information about participating in clinical research visit NIH Clinical Research Trials and You. Learn about clinical trials currently looking for people with transverse myelitis at Clinicaltrials.gov.
Where can I find more information about transverse myelitis?
Information may be available from the following resources:
Christopher and Dana Reeve Foundation
Phone: 800-225-0292
National Organization for Rare Disorders (NORD)
Phone: 617-249-7300 or 800-999-6673
Siegel Rare Neuroimmune Association
Phone: 855-380-3330
The Guthy-Jackson Charitable Foundation
Phone: 310- 620-3074
Content source: https://www.ninds.nih.gov/health-information/disorders/transverse-myelitis Accessed July 17, 2023.
The information in this document is for general educational purposes only. It is not intended to substitute for personalized professional advice. Although the information was obtained from sources believed to be reliable, MedLink, its representatives, and the providers of the information do not guarantee its accuracy and disclaim responsibility for adverse consequences resulting from its use. For further information, consult a physician and the organization referred to herein.
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125